drugset / Trial / NCT01011959

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

NCT01011959

Phase 1 Completed 60 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.

Timeline

Start
2008-12
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sarilumab Monoclonal antibody

Indications